Vivos Therapeutics (VVOS) Invested Capital (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Invested Capital data on file, last reported at $6.2 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $6.2 million, up 39.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.2 million (up 39.8% YoY), and the FY2025 annual result was -$1.4 million, down 117.37% from the prior year.
• Invested Capital improved to $6.2 million in Q1 2026 per VVOS's latest filing, from -$1.4 million in the prior quarter.
• Over five years, Invested Capital peaked at $21.0 million in Q1 2022 and troughed at -$1.4 million in Q4 2025.
• A 5-year average of $5.8 million and a median of $4.8 million in 2022 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2024 and 2025: Invested Capital soared 16563.04% in 2024, then plunged 117.37% in 2025.
• A 5-year view of Invested Capital shows it stood at $4.8 million in 2022, then plunged by 91.44% to $411000.0 in 2023, then soared by 1835.28% to $8.0 million in 2024, then slumped by 117.37% to -$1.4 million in 2025, then jumped by 545.8% to $6.2 million in 2026.
• Business Quant data shows VVOS's Invested Capital at $6.2 million in Q1 2026, -$1.4 million in Q4 2025, and $2.9 million in Q3 2025.